Associations - IDH1 mutation

IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: A2 - Guideline EHA 2022 - 4 days (NewA2)	venetoclax Sensitive: A2 - Guideline EHA 2022 - 4 days - (New C3)
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials EHA 2022 - 4 days (NewC3)	cytarabine / daunorubicin liposomal formulation Sensitive: C3 – Early Trials EHA 2022 - 4 days - (New C3)
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	ivosidenib Sensitive: A1 - Approval N Engl J Med - 3 weeks (NewA1)	ivosidenib Sensitive: A1 - Approval N Engl J Med - 3 weeks - (New B)
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval	ivosidenib Sensitive: A1 - Approval
IDH1 mutation IDH1 mutation	Sarcoma Sarcoma	IDH1 mutation IDH1 mutation	Sarcoma Sarcoma	ivosidenib Sensitive: A2 - Guideline	ivosidenib Sensitive: A2 - Guideline
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	temozolomide gel Sensitive: B - Late Trials	temozolomide gel Sensitive: B - Late Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	gilteritinib Resistant: B - Late Trials	gilteritinib Resistant: B - Late Trials
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	temozolomide Sensitive: B - Late Trials	temozolomide Sensitive: B - Late Trials
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	PCV Sensitive: B - Late Trials	PCV Sensitive: B - Late Trials
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	ivosidenib Sensitive: C1 - Off-label	ivosidenib Sensitive: C1 - Off-label
IDH1 mutation IDH1 mutation	Astrocytoma Astrocytoma	IDH1 mutation IDH1 mutation	Astrocytoma Astrocytoma	temozolomide Sensitive: C2 – Inclusion Criteria	temozolomide Sensitive: C2 – Inclusion Criteria
IDH1 mutation IDH1 mutation	Glioblastoma GBM	IDH1 mutation IDH1 mutation	Glioblastoma GBM	temozolomide Sensitive: C2 – Inclusion Criteria	temozolomide Sensitive: C2 – Inclusion Criteria
IDH1 mutation IDH1 mutation	Glioblastoma GBM	IDH1 mutation IDH1 mutation	Glioblastoma GBM	NEO100 Sensitive: C2 – Inclusion Criteria	NEO100 Sensitive: C2 – Inclusion Criteria
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	AG-881 Sensitive: C2 – Inclusion Criteria	AG-881 Sensitive: C2 – Inclusion Criteria
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	TG02 Sensitive: C3 – Early Trials	TG02 Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV-621 Sensitive: C3 – Early Trials	venetoclax + ABBV-621 Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + ivosidenib Sensitive: C3 – Early Trials	venetoclax + ivosidenib Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	FT-2102 Sensitive: C3 – Early Trials	FT-2102 Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Glioblastoma GBM	IDH1 mutation IDH1 mutation	Glioblastoma GBM	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	CFI-400945 Sensitive: C3 – Early Trials	CFI-400945 Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials	venetoclax + midostaurin Resistant: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials	venetoclax + gilteritinib Resistant: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials	venetoclax + sorafenib Resistant: C3 – Early Trials
IDH1 mutation IDH1 mutation	Chronic Myelomonocytic Leukemia CMML	IDH1 mutation IDH1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	BAY1436032 Sensitive: C3 – Early Trials	BAY1436032 Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	IDH1 mutation IDH1 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: C3 – Early Trials	PCV Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Sarcoma Sarcoma	IDH1 mutation IDH1 mutation	Sarcoma Sarcoma	olaparib Sensitive: C3 – Early Trials	olaparib Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Myelodysplastic Syndrome MDS	IDH1 mutation IDH1 mutation	Myelodysplastic Syndrome MDS	venetoclax + ivosidenib Sensitive: C3 – Early Trials	venetoclax + ivosidenib Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	MEN1703 Sensitive: C3 – Early Trials	MEN1703 Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	metformin Sensitive: C3 – Early Trials	metformin Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Sarcoma Sarcoma	IDH1 mutation IDH1 mutation	Sarcoma Sarcoma	metformin Sensitive: C3 – Early Trials	metformin Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	metformin Sensitive: C3 – Early Trials	metformin Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Biliary Tract Cancer Biliary Tract Cancer	IDH1 mutation IDH1 mutation	Biliary Tract Cancer Biliary Tract Cancer	dasatinib Sensitive: C3 – Early Trials	dasatinib Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	CDIAG Sensitive: C3 – Early Trials	CDIAG Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Glioblastoma GBM	IDH1 mutation IDH1 mutation	Glioblastoma GBM	AV-GBM-1 Sensitive: C3 – Early Trials	AV-GBM-1 Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	ABBV-744 Sensitive: D – Preclinical	ABBV-744 Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	IDH1 mutation IDH1 mutation	Acute Myelogenous Leukemia AML	venetoclax + IACS-010759 Sensitive: D – Preclinical	venetoclax + IACS-010759 Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioblastoma GBM	IDH1 mutation IDH1 mutation	Glioblastoma GBM	panobinostat Sensitive: D – Preclinical	panobinostat Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	pamiparib Sensitive: D – Preclinical	pamiparib Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical	AZD0530 Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	bosutinib Sensitive: D – Preclinical	bosutinib Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	ponatinib Sensitive: D – Preclinical	ponatinib Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	dasatinib Sensitive: D – Preclinical	dasatinib Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	APO866 Sensitive: D – Preclinical	APO866 Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Leukemia Leukemia	IDH1 mutation IDH1 mutation	Leukemia Leukemia	venetoclax Sensitive: D – Preclinical	venetoclax Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	cetuximab Resistant: D – Preclinical	cetuximab Resistant: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	sunitinib Sensitive: D – Preclinical	sunitinib Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	bevacizumab Sensitive: D – Preclinical	bevacizumab Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	panobinostat Sensitive: D – Preclinical	panobinostat Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	NPI-0052 Sensitive: D – Preclinical	NPI-0052 Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical	omacetaxine mepesuccinate Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	regorafenib Sensitive: D – Preclinical	regorafenib Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	dactinomycin Sensitive: D – Preclinical	dactinomycin Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	romidepsin Sensitive: D – Preclinical	romidepsin Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	daunorubicin Sensitive: D – Preclinical	daunorubicin Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	teniposide Sensitive: D – Preclinical	teniposide Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	gemcitabine Sensitive: D – Preclinical	gemcitabine Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	paclitaxel Sensitive: D – Preclinical	paclitaxel Sensitive: D – Preclinical
IDH1 mutation IDH1 mutation	Glioma Glioma	IDH1 mutation IDH1 mutation	Glioma Glioma	decitabine Sensitive: D – Preclinical	decitabine Sensitive: D – Preclinical